Stockscreener 앱 받기
23.50
0.32%
-0.075
Sutro Biopharma Inc 주식(STRO)의 최신 뉴스
Analyst James Shin Raises Price Target for Sutro Biopharma (STRO) to $55.00 | STRO Stock News - GuruFocus
Deutsche Bank Aktiengesellschaft Issues Positive Forecast for Sutro Biopharma (NASDAQ:STRO) Stock Price - MarketBeat
Deutsche Bank Adjusts Sutro Biopharma Price Target to $55 From $51, Maintains Buy Rating - marketscreener.com
HC Wainwright Predicts Sutro Biopharma FY2030 Earnings - MarketBeat
This Ralph Lauren Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga
Wells Fargo Upgrades Sutro Biopharma (STRO) with Significant Pri - GuruFocus
Sutro Biopharma (NASDAQ:STRO) Raised to "Overweight" at Wells Fargo & Company - MarketBeat
Sutro Biopharma (NASDAQ:STRO) Raised to Buy at HC Wainwright - MarketBeat
Wells Fargo Upgrades Sutro Biopharma to Overweight From Equal Weight, Adjusts PT to $27 From $8 - marketscreener.com
H.C. Wainwright upgrades Sutro Biopharma stock rating to buy By Investing.com - Investing.com Canada
Sutro's FY25 Net Loss Narrows; On Track To Report Initial Phase 1 Data Of STRO-004 In Mid-2026 - RTTNews
STRO Stock: HC Wainwright & Co. Upgrades Sutro Biopharma | STRO Stock News - GuruFocus
Sutro Biopharma (STRO) Receives Upgrade with Promising Outlook - GuruFocus
Sutro Biopharma Reports 2025 Financial Results, Advances Dual-Payload ADC Pipeline, and Extends Cash Runway to 2028 - Minichart
HC Wainwright & Co. upgrades Sutro Biopharma (STRO) - MSN
Sutro Biopharma Annual Report 2023: Business Overview, Risk Factors, and Financial Analysis - Minichart
Sutro Biopharma (NASDAQ: STRO) launches $100M ATM program with TD Cowen - Stock Titan
Sutro Biopharma Ends ATM Agreement After 2025 Results - TipRanks
Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights - Bitget
Sutro Biopharma (NASDAQ:STRO) Issues Earnings Results - MarketBeat
Sutro Biopharma 2025 10-K: $102.5M revenue, $(22.49) EPS - TradingView
Sutro Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Sutro Biopharma (NASDAQ: STRO) expands ADC pipeline and monetizes partnerships - Stock Titan
Revenue jumps as Sutro Biopharma (NASDAQ: STRO) narrows 2025 loss - Stock Titan
Q4 financial results released by Sutro Biopharma with operational update - Traders Union
BRIEF-Sutro Biopharma FY Revenue USD 102.484 Million Vs. IBES Estimate USD 99.2 Million - TradingView
Sutro says cash lasts to 2028 as cancer drug pipeline advances - Stock Titan
Sutro Biopharma (STRO) 2024 Wells Fargo Healthcare Conference Summary - Quartr
If You Invested $1,000 in Sutro Biopharma (STRO) - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Analyst Upgrade: Is now the right time to enter Sutro Biopharma Inc2026 Summary & Community Consensus Trade Alerts - baoquankhu1.vn
Aug Action: What are Sutro Biopharma Inc.’s recent SEC filings showing2026 Retail Activity & AI Based Trade Execution Alerts - baoquankhu1.vn
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Aug Rallies: Why is Allegro MicroSystems Inc. stock going down2026 Update & Accurate Trade Setup Notifications - baoquankhu1.vn
Sutro Biopharma, Inc. (NASDAQ:STRO) Short Interest Down 19.8% in February - MarketBeat
Sutro Biopharma: ADC Developer With Poor Track Record Aims For Positive 2026 (NASDAQ:STRO) - Seeking Alpha
Sutro Biopharma, Inc. to Present at 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026 - Quiver Quantitative
Fed Meeting: What is the Moat Score of Sutro Biopharma Inc2026 Retail & Daily Growth Stock Tips - baoquankhu1.vn
Sutro Biopharma (STRO) surges 11.9%: Is this an indication of further gains? - MSN
Sutro Biopharma Hits New 52-Week High of $25.68, Soars 556.88% - Markets Mojo
Sutro Biopharma Inc expected to post a loss of $4.34 a shareEarnings Preview - TradingView
Aug Swings: Can Sutro Biopharma Inc. continue delivering strong returns2026 Pullback Review & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Sutro Biopharma Hits New 52-Week High of $21.40, Soars 453% - Markets Mojo
Sutro Biopharma (STRO) GC exercises RSUs as shares withheld for taxes - Stock Titan
Sutro Biopharma Hits New 52-Week High at $20.47, Soars 430% - Markets Mojo
Sutro Biopharma Hits New 52-Week High of $20.93, Up 431.69% - Markets Mojo
Sutro Biopharma Hits New 52-Week High of $20.48, Up 431.69% - Markets Mojo
Sutro Biopharma (STRO) to Release Quarterly Earnings on Thursday - MarketBeat
Sutro Biopharma: Transformed leadership and advanced ADC pipeline drive clinical progress, with key data due mid-year - TradingView
Sutro Biopharma: Transformed leadership and advanced ADC platform drive rapid clinical progress and innovation - TradingView
Sutro Biopharma (STRO) GC reports new RSUs, options and tax share withholdings - Stock Titan
Sutro Biopharma (NASDAQ: STRO) CSO receives RSUs and options - Stock Titan
Sutro Biopharma (STRO) CFO awarded 40,000 options and 5,000 RSUs - Stock Titan
Sutro Biopharma (STRO) CEO receives RSU and option grants, shares withheld for taxes - Stock Titan
174,843 Shares in Sutro Biopharma, Inc. $STRO Purchased by GSA Capital Partners LLP - MarketBeat
Sutro Biopharma, Inc. (STRO) Presents at 16th Annual World ADC London SummitSlideshow - Seeking Alpha
STRO PE Ratio & Valuation, Is STRO Overvalued - Intellectia AI
STRO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Sutro Biopharma to participate in key investor conferences - Traders Union
Sutro Biopharma to Participate in Upcoming Investor Conferences - marketscreener.com
Sutro Biopharma lines up March health-care investor talks in Boston and Miami - Stock Titan
Sutro Biopharma Announces Participation at the 16th World ADC London Summit - The Manila Times
World ADC London panels spotlight Sutro Biopharma’s dual-payload ADCs - Stock Titan
Earnings Miss: Is Sutro Biopharma Inc a stock for growth or value investors2025 Key Highlights & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
1.82%
자본화:
|
볼륨(24시간):